FDA warns of brain problem with Glaxo seizure drug

Aug 12, 2010

(AP) -- Federal health regulators are warning doctors and patients that a seizure drug from GlaxoSmithKline can cause rare inflammation of the brain and spinal cord.

The Food and Administration says it is working with the British drugmaker Glaxo to add new warnings and labeling information to the company's drug Lamictal.

The agency said it has received reports of 40 cases of aseptic meningitis since Lamictal's approval in 1994 and last November. Thirty-five patients needed to be hospitalized, the agency said in a statement.

Aseptic meningitis is a dangerous inflammation of the brain and that can cause headache, fever, chills and vomiting. The problem can be caused by viruses, toxins and certain medications.

Explore further: Determine patient preferences by means of conjoint analysis

not rated yet
add to favorites email to friend print save as pdf

Related Stories

FDA expands meningitis vaccine approval

Oct 22, 2007

The U.S. Food and Drug Administration has expanded approval for the use of Menactra, a bacterial meningitis vaccine, to children ages 2 to 10.

12 cases of brain disease after vaccines

Oct 24, 2006

The U.S. Food and Drug Administration said 12 cases of a neurological disorder have been reported following the application of a meningococcal vaccine.

Anti-cancer drug damages brain vessels

Feb 11, 2008

New research may help explain why an anti-cancer drug causes potentially fatal brain inflammation in certain patients. Scientists at Harvard Medical School mimicked the drug's activity in mice and found that it damaged the ...

Recommended for you

Determine patient preferences by means of conjoint analysis

9 hours ago

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

neiorah
not rated yet Aug 12, 2010
This is just lovely bc my daughter has been on this drug for the past year. It has been a bad year for her physically and now i think I know why.